MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Pre-Mkt 06-09 04:17:27 EDT

18.00

+0.10

+0.56%

盘前18.00

+0.000.00%

04:02 EDT

High18.27	Low17.84	Vol1.21M
Open18.24	D1 Closing17.90	Amplitude2.40%
Mkt Cap1.33B	Tradable Cap707.66M	Total Shares73.62M
T/O21.88M	T/O Rate3.09%	Tradable Shares39.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":18,"timestamp":1780948800000,"preClose":17.9,"halted":0,"volume":1213653,"hourTrading":{"tag":"盘前","latestPrice":18,"preClose":18,"latestTime":"04:02 EDT","volume":12,"amount":223.36729200000002,"timestamp":1780992175985,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00558659217877103,"floatShares":39314700,"shares":73615396,"eps":-3.869523,"marketStatus":"Pre-Mkt","change":0.1,"latestTime":"06-09 04:17:27 EDT","open":18.24,"high":18.265,"low":17.835,"amount":21876509.180673,"amplitude":0.024022,"askPrice":19.78,"askSize":1,"bidPrice":16.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.869523,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781011800000},"marketStatusCode":1,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":18,"preHourTrading":{"tag":"盘前","latestPrice":18,"preClose":18,"latestTime":"04:02 EDT","volume":12,"amount":223.36729200000002,"timestamp":1780992175985,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":18.08,"preClose":18,"latestTime":"19:58 EDT","volume":21299,"amount":384527.7272,"timestamp":1780963133531,"change":0.08,"changeRate":0.004444,"amplitude":0.015},"volumeRatio":1.8122863342764208,"impliedVol":0.8003,"impliedVolPercentile":0.276},"requestUrl":"/m/hq/s/MLTX/wiki","defaultTab":"wiki","newsList":[{"id":"2642058433","title":"Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642058433","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642058433?lang=en_us&edition=fundamental","pubTime":"2026-06-09 00:40","pubTimestamp":1780936810,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immuno...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-artiva-biotherapeutics-inc-artv-moonlake-immunotherapeutics-mltx-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-artiva-biotherapeutics-inc-artv-moonlake-immunotherapeutics-mltx-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","MLTX","BK4137","LU0029874061.USD","BK4139","BK4581","LABU","BK4588","LU0128526141.USD","MBX","BK4585","BK4007","HCSG","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642433093","title":"Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX","url":"https://stock-news.laohu8.com/highlight/detail?id=2642433093","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642433093?lang=en_us&edition=fundamental","pubTime":"2026-06-09 00:30","pubTimestamp":1780936223,"startTime":"0","endTime":"0","summary":"Moonlake Immunotherapeutics ($MLTX) announced an update on their ongoing clinical study. The Phase 3 study titled “A Phase 3, Randomized, Double-bl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moonlakes-phase-3-hidradenitis-trial-hits-completion-setting-up-key-catalyst-for-mltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moonlakes-phase-3-hidradenitis-trial-hits-completion-setting-up-key-catalyst-for-mltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641448191","title":"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641448191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641448191?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:50","pubTimestamp":1780919417,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and Moo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-hinge-health-inc-class-a-hnge-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-hinge-health-inc-class-a-hnge-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZLL34.SGD","XLV","LU0058720904.USD","LABU","LU1674673691.USD","LU1778281490.HKD","BK4568","BK4139","BK4585","LU1066051498.USD","SG9999015945.SGD","SG9999015952.SGD","IE00BZ1G4Q59.USD","BK4196","LU0882574055.USD","LU1571399168.USD","LU1934455277.USD","GILD","LU1037948541.HKD","IE00B19Z3581.USD","BK4583","BK4578","LU0320765992.SGD","LU0029874061.USD","XBI","BK4550","LU1934455863.HKD","LU0114720955.EUR","LU0289739699.SGD","LU0965508806.USD","IE00BSNM7G36.USD","LU0965509283.SGD","MLTX","LU1430594728.SGD","LU2089984988.USD","LU0128526141.USD","LU0823416689.USD","LU1585245621.USD","BK4566","LU0122379950.USD","LU2468319806.SGD","LU0861579265.USD","SG9999015978.USD","HNGE","LU1934455194.USD","LU2087621335.USD","IE0002270589.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641352486","title":"MoonLake Immunotherap Price Target Maintained With a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641352486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641352486?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:53","pubTimestamp":1780915980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:53 ET (10:53 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641213181","title":"MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2641213181","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641213181?lang=en_us&edition=fundamental","pubTime":"2026-06-06 16:12","pubTimestamp":1780733532,"startTime":"0","endTime":"0","summary":"Regulatory milestone draws attention to MoonLake Immunotherapeutics stock\nMoonLake Immunotherapeutics (MLTX) recently reported encouraging outcomes from its final pre application discussions with the FDA for sonelokimab, a key regulatory milestone that appears to have sharpened investor focus on the stock.\nSee our latest analysis for MoonLake Immunotherapeutics.\nThe latest FDA progress comes after a choppy period for the stock, with the 1 year total shareholder return down 61.82% even as the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-mltx-valuation-after-fda-progres","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-mltx-valuation-after-fda-progres","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","PRGS","BK4097","LU2065732104.USD","MLTX","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640953332","title":"MoonLake Immunotherapeutics signs commercial supply pact with Vetter Pharma for prefilled application systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953332","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953332?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:21","pubTimestamp":1780309272,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics signed a master commercial supply agreement with Vetter on May 22, 2026, covering manufacture of pre-filled application systems.The deal uses product-specific schedules for services and pricing, with Vetter able to adjust pricing for documented cost increases.A separate capacity agreement requires binding demand forecasts, with Vetter reserving annual filling capacity up to a maximum quantity.MoonLake may owe capacity compensation if orders fall below minimum commitments or if purchase orders are not provided for the binding period.The master supply agreement allows termination for uncured material breach, bankruptcy, or certain change-of-control events; no-cause termination requires 12 months’ notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL45gWcg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863485","title":"Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863485?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:50","pubTimestamp":1779209411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR), MoonLake Immunotherapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4568","LU0128526141.USD","LU0029874061.USD","XLV","HCSG","DWTX","BK4581","BK4588","VIR","BK4137","BK4139","XBI","LABU","BK4535","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635006654","title":"LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635006654","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635006654?lang=en_us&edition=fundamental","pubTime":"2026-05-16 22:35","pubTimestamp":1778942159,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on MoonLake Immunotherapeutics today and set a price target of $33.00. Katkhuda cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-their-buy-rating-for-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-their-buy-rating-for-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215927","title":"MoonLake Immunotherap Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215927?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:31","pubTimestamp":1778585460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 07:31 ET (11:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213014","title":"Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213014?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:16","pubTimestamp":1778584617,"startTime":"0","endTime":"0","summary":"In a report released today, Serge Belanger from Needham maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $30.00. Acco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634200218","title":"MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2634200218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634200218?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:04","pubTimestamp":1778583890,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P0QR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634089292","title":"MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2634089292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634089292?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:55","pubTimestamp":1778579737,"startTime":"0","endTime":"0","summary":"BTIG analyst Julian Harrison reiterated a Buy rating on MoonLake Immunotherapeutics yesterday and set a price target of $30.00. Julian Harrison has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-buy-rating-reiterated-on-de-risked-path-to-2026-bla-and-robust-slk-data-30-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-buy-rating-reiterated-on-de-risked-path-to-2026-bla-and-robust-slk-data-30-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634942238","title":"Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2634942238","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634942238?lang=en_us&edition=fundamental","pubTime":"2026-05-11 22:45","pubTimestamp":1778510736,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on MLTX stock, giving a Buy rating today. Phil Nadeau has given his Buy rating due...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/phil-nadeau-reiterates-buy-on-moonlake-immunotherapeutics-as-sonelokimab-advances-toward-2027-launch-with-3b-peak-sales-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/phil-nadeau-reiterates-buy-on-moonlake-immunotherapeutics-as-sonelokimab-advances-toward-2027-launch-with-3b-peak-sales-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKIS","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634281751","title":"MoonLake Q1 net loss widens 71.9% to $69.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634281751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634281751?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:56","pubTimestamp":1778504207,"startTime":"0","endTime":"0","summary":"Moonlake Immunotherapeutics posted a net loss of USD 69.71 million, widening 71.9% year over year, while operating loss deepened 47.5% to USD 70.02 million.Research and development expense climbed 49.5% to USD 54.52 million, while general and administrative costs increased 40.7% to USD 15.51 million.Cash, cash equivalents, and short-term marketable securities totaled USD 357.9 million, with cash used in operating activities rising to USD 66.29 million from the prior-year period.Moonlake expects to submit a BLA for sonelokimab in hidradenitis suppurativa at end of third-quarter 2026, targeting first US commercial launch in second-half 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7SjbYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634428694","title":"MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634428694","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634428694?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:00","pubTimestamp":1778500818,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings SummaryMoonLake Immunotherapeutics MLTX.OQ reported a quarterly adjusted loss of 98 cents per share for the quarte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O14I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634428379","title":"Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634428379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634428379?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498448,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX), Axsome Therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-axsome-therapeutics-axsm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-axsome-therapeutics-axsm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0128526141.USD","BLSG","BK4581","BK4139","MLTX","BK4007","LABU","AXSM","XBI","BK4505","BK4112","BK4585","BK4588","BLSX","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288751","title":"MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288751?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 07:00 ET (11:00 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634640597","title":"MoonLake Immunotherapeutics Q1 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2634640597","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634640597?lang=en_us&edition=fundamental","pubTime":"2026-05-11 15:43","pubTimestamp":1778485390,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics  reported a Q1 net loss Sunday of $0.98 per diluted share, widening from a loss of $0.63 a year earlier.Analysts surveyed by FactSet expected a loss of $0.98.As of March 31, 2026, the company held $357.9 million in cash, cash equivalents and short-term marketable debt securities. It added that it expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to the end of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426447","title":"MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426447","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634426447?lang=en_us&edition=fundamental","pubTime":"2026-05-11 03:10","pubTimestamp":1778440205,"startTime":"0","endTime":"0","summary":"Clear Street says MoonLake Immunotherapeutics’s (MLTX) positive pre-application meeting with the restores to its “prior strong positioning” in the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-fda-meeting-yields-best-in-class-label-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-fda-meeting-yields-best-in-class-label-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4585","BK4588","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426637","title":"MoonLake says aligned with FDA on submission plans for sonelokimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426637","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634426637?lang=en_us&edition=fundamental","pubTime":"2026-05-11 02:50","pubTimestamp":1778439045,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) announced a “positive” outcome of its final pre-BLA meeting held on April 1 with the FDA on the HS program of it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-says-aligned-with-fda-on-submission-plans-for-sonelokimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-says-aligned-with-fda-on-submission-plans-for-sonelokimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4585","BK4588","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":-0.0436},{"period":"1month","weight":0.0551},{"period":"3month","weight":-0.0185},{"period":"6month","weight":0.232},{"period":"1year","weight":-0.616},{"period":"ytd","weight":0.3657}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.083781},{"month":3,"riseRate":0.666667,"avgChangeRate":0.033144},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.114037},{"month":5,"riseRate":0.5,"avgChangeRate":0.100872},{"month":6,"riseRate":0.666667,"avgChangeRate":0.136386},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction